

Our Investigational COVID-19 Vaccine Candidate

How It Works



Our investigational COVID-19 vaccine candidate* is a monovalent, recombinant, replication incompetent **adenovirus type 26 vectored vaccine**

Our vaccine candidate was developed using Janssen's AdVac® technology.

This technology was also used to develop Janssen's European Commission-approved **Ebola vaccine regimen and construct our HIV, RSV and Zika investigational vaccine candidates.**

200,000+ people have been vaccinated to date using the AdVac® platform.



We use a piece of DNA that codes for the coronavirus "spike" and place it inside a **non-replicating adenoviral vector. The vaccine candidate cannot cause COVID-19**



Our Clinical Progress



~45,000 participants enrolled in our single-dose Phase 3 ENSEMBLE trial



Aiming for **~30,000** participants to be enrolled in our two-dose regimen Phase 3 ENSEMBLE 2 trial



ENSEMBLE Phase 3 topline data demonstrated that the vaccine candidate **met primary endpoints**



13 countries have **ongoing Phase 1, 2, 3 trials**


Vaccine Manufacturing, Supply and Access



The Company's anticipated manufacturing timeline will enable it to **meet its 2021 supply commitments**, including those signed with governments and global organizations



Our vaccine candidate is estimated to remain stable for **two years at -20°C / -4°F** and at least **three months of which can be at temperatures of 2-8° C / 36°-46° F**



Most refrigerators store food at or below **4° C / 40° F** and freezers clock in at or below **-18° C / 0° F**




Transportation and storage of our vaccine candidate is **in line with conventional vaccine distribution**

Access to a Vaccine



We aim to **make our vaccine accessible** on a **not-for-profit** basis for emergency pandemic use



We plan to allocate up to **500 million vaccine doses to lower income countries**

J&J Works in Partnership



Johnson & Johnson is **collaborating to help ensure our research platforms and outbreak expertise can be maximized** to stem this pandemic. We have worked closely with clinical trial investigators and governments around the world, in addition to partnering with the **Biomedical Advanced Research and Development Authority (BARDA), the National Institutes of Health (NIH) and the Beth Israel Deaconess Medical Center (BIDMC).**